weight loss drug - HealthQuill

Novo Nordisk will invest 6.4 billion reais ($1.05 billion) in Brazil’s Monte Claros to expand its production of injectable treatments for people living with obesity and chronic diseases.

Novo Nordisk to invest $1.05b in Monte Claros facility in Brazil

HQ Team April 10, 2025: Novo Nordisk will invest 6.4 billion reais ($1.05 billion) in Brazil’s Monte Claros to expand its production of.

by HealthQuill
April 10, 2025
0 Comments

Tirzepatide is an approved GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) treatment for chronic weight management, commercialised as Zepbound in the US and Mounjaro in some global markets outside the US.

Drugs Health Pharma

Eli Lilly’s Zepbound resolves sleep apnea in more than half of trial patients

Tirzepatide, an obesity drug of Eli Lilly and Company, has helped resolve moderate-to-severe obstructive sleep apnea in 52.% of adult patients in two.

by HealthQuill
June 22, 2024
0 Comments

Novo Nordisk, Europe’s most valuable company, has raised its 2024 revenue outlook on the back of its popular weight-loss drug Wegovy, as it announced its January to March operating profit rose 27% to Danish kroner 31.8 billion.

Drugs Health Pharma

Novo Nordisk raises sales forecast on strong demand for anti-obesity drug

HQ Team May 2, 2024: Novo Nordisk, Europe’s most valuable company, has raised its 2024 revenue outlook on the back of its popular.

by HealthQuill
May 2, 2024
0 Comments

US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side effects.

Drugs Health Pharma

Viking Therapeutics’ weight-loss drug shows ‘positive’ results in early trials

US-based biotechnology company Viking Therapeutics Inc., reported “positive” results from its early-stage weight-loss oral drug and the pill showed mild to moderate side.